Conference Program

Thursday, November 2

8:00 a.m. Registration
8:55 a.m. Welcome Remarks

Keynote

Chair:

9:00 a.m. Vaccines for HIV Prevention and Treatment
Nelson Michael, U.S. Military HIV Research Program, USA

Session 1 Vaccines and antibodies

Chair:

10:00 a.m. CD8+ T cell responses: Can they contribute to HIV/SIV cure?
Louis Picker, Oregon Health & Science University, USA

10:30 a.m. Virus-antibody co-evolution in HIV infected individuals
Nicola Doria-Rose, National Institute of Health, USA

11:00 a.m. Coffee break

11:30 a.m. Toward eliciting antibodies to order: reductionist HIV vaccine design to elicit broadly neutralizing antibodies with pre-specified genetic and structural features
Bill Schieff, Scripps Research Institute, USA

12:00 p.m. Toward sustained, effective, and universal protection from HIV-1
Mike Farzan, The Scripps Research Institute, USA

12:30 p.m. Lunch

Session 2 Cure research

Chair:

2:00 p.m. Latency reversal and viral clearance: preliminary studies
David Margolis, UNC HIV Cure Center, USA

2:30 p.m. Reservoir markers for cure research and clinical trials
Christine Rouzioux, Necker Hospital, France
3:00 p.m.  
**Approaches for detecting and targeting HIV**
**Bonnie Howell**, Merck, USA

3:15 p.m.  
**Coffee Break**

3:30 p.m.  
**Compartmentalization of immune recovery in terminal ileum and rectal galt with art in primary HIV infection**
**John Thornhill**, Imperial College London, UK

### Session 3  
**Viral reservoirs**

**Chair:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m.</td>
<td>Tracking the HIV reservoir</td>
<td><strong>Monsef Benkirane</strong>, Institute of Human Genetics, France</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>In vivo analysis of HIV reservoirs</td>
<td><strong>J. Victor Garcia</strong>, University of North Carolina at Chapel Hill, USA</td>
</tr>
<tr>
<td>4:45 p.m.</td>
<td>Viral dynamics of the peripheral latent reservoir after analytical treatment interruption</td>
<td><strong>Brenda Salantes</strong>, University of Pennsylvania, USA</td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td>HIV-1 reservoirs in CD4 T cell subpopulations</td>
<td><strong>Mathias Lichterfeld</strong>, Harvard Medical School, USA</td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td>Inhibition of HIV reactivation in brain cells by AAV-mediated delivery of CRISPR/Cas9</td>
<td><strong>Christine Kunze</strong>, Helmholtz Zentrum München, Germany</td>
</tr>
</tbody>
</table>

5:45 p.m.  
**Reception**

7:00 p.m.  
**Close of day**

---

**Friday, November 3**

### Keynote

**Chair:**

9:00 a.m.  
**HIV-1 persists and evolves within lymph tissue due to low drug penetration**
**Steven Wolinsky**, Northwestern University, USA

### Session 4  
**HIV transmission, restriction and pathogenesis**

**Chair:**

10:00 a.m.  
**Role of type 1 interferons in restriction of HIV-1 transmission**
**Persephone Borrow**, University of Oxford, UK

10:30 a.m.  
**Eliminating productively and latently infected cells with antibodies**
**Olivier Schwartz**, Institute Pasteur, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 5</th>
<th>Session 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m.</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>11:20 a.m.</td>
<td><em>C-type lectin receptors control HIV-1 infection and immunity</em></td>
<td><em>Maturation and persistence of broadly neutralizing antibodies</em></td>
</tr>
<tr>
<td></td>
<td><strong>Teunis Geijtenbeek</strong>, Academic Medical Center Amsterdam, The Netherlands</td>
<td><strong>Penny Moore</strong>, National Institute for Communicable Disease, South Africa</td>
</tr>
<tr>
<td>11:50 p.m.</td>
<td><em>HIV-1 restriction factors and viral countermeasures</em></td>
<td><em>Immunological effects of tuberculosis and ART timing in highly immunosuppressed HIV+ patients</em></td>
</tr>
<tr>
<td></td>
<td><strong>Frank Kirchhoff</strong>, Ulm University, Germany</td>
<td><strong>Anne Goldfeld</strong>, Harvard University, USA</td>
</tr>
<tr>
<td>12:20 p.m.</td>
<td><em>HIV-1 balances the fitness costs of disrupting the host actin cytoskeleton by ensuring systemic persistence after mucosal transmission</em></td>
<td><em>Biomedical Factors influencing HIV risk in young women</em></td>
</tr>
<tr>
<td></td>
<td><strong>Shariq Usmani</strong>, Massachusetts General Hospital, USA</td>
<td><strong>Jo-Ann Passmore</strong>, Institute of Infectious Disease and Molecular Medicine, South Africa</td>
</tr>
<tr>
<td>12:35 p.m.</td>
<td>Lunch and Poster Session</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3:45 p.m.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Close of conference</em></td>
</tr>
</tbody>
</table>

**Session 5: Viral immunity**

*Chair:*

- 2:15 p.m. *Shut down of T cell activity in chronic HIV infection*
  - **Hendrik Streeck**, Essen University Hospital, Germany

- 2:45 p.m. *NK cell mediated recognition of HIV-1*
  - **Marcus Altfeld**, Heinrich Pette Institute, Germany

- 3:15 p.m. *Understanding HIV persistence and Immunity using virus sequence analysis*
  - **Eli Boritz**, National Institute of Health, USA

3:45 p.m. Coffee Break

**Session 6: Lessons from cohorts**

*Chair:*

- 4:15 p.m. *Maturation and persistence of broadly neutralizing antibodies*
  - **Penny Moore**, National Institute for Communicable Disease, South Africa

- 4:45 p.m. *Immunological effects of tuberculosis and ART timing in highly immunosuppressed HIV+ patients*
  - **Anne Goldfeld**, Harvard University, USA

- 5:15 p.m. *Biomedical Factors influencing HIV risk in young women*
  - **Jo-Ann Passmore**, Institute of Infectious Disease and Molecular Medicine, South Africa

5:45 p.m. Close of conference